Company news
Thiogenesis Therapeutics Corp news in 2025
Thiogenesis Therapeutics Corp's news releases, calls and decks from 2025, newest first.
Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th
December 9, 2025
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
November 24, 2025
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
November 4, 2025
Thiogenesis Announces Extension to Investor Relations Agreement
October 3, 2025
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
September 11, 2025
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares
August 14, 2025
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares
August 1, 2025
Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares
July 29, 2025
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
July 17, 2025
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
June 25, 2025
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
June 20, 2025
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
June 17, 2025
Thiogenesis Announces Grant of Stock Options
June 12, 2025
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum
June 11, 2025
Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")
May 14, 2025
Thiogenesis Announces European Consulting and Investor Relations Agreement
February 20, 2025
Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
February 12, 2025
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
January 27, 2025